Essafi Mohammed Amine, Bouabdellaoui Latifa, Aynaou Hayat, Salhi Houda, El Ouahabi Hanan
Endocrinology, Diabetology, Metabolic Diseases and Nutrition, Hassan II University Hospital Center, Fez, MAR.
Cureus. 2022 Apr 25;14(4):e24469. doi: 10.7759/cureus.24469. eCollection 2022 Apr.
Aim Our study aims to assess the prevalence of metabolic syndrome (MS) in patients with diabetes mellitus, identify its determinants, and determine the correlation between MS and degenerative complications. Method A retrospective, descriptive and analytic study was conducted at the Endocrinology, Diabetology, and Nutrition department of the Hassan II University Hospital in Fez, over the period between January 2009 and January 2019. We included in our study all type 1 and type 2 diabetic patients. The presence of metabolic syndrome was defined according to the criteria of the International Diabetes Federation (IDF) and American Heart Association/National Heart, Lung and Blood Institute (AHA / NHLBI) Joint Scientific Statement (2009). The data were entered in Microsoft Excel (Microsoft Corporation. 2018). and analyzed using SPSS software (IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp). Result A total of 1034 patients were included in this study; 78.7% were type 2 diabetics (T2D) and 21.3% were type 1 diabetics (T1D). The average age was 52,06 ± 17,33 years in T2D and 27,04 ± 9,66 years in T1D. 65,5% were females. The prevalence of metabolic syndrome was 78.4% for T2D, and 27.3% for T1D. The most common abnormality was high blood pressure in T2D (87.7%), and visceral obesity in T1D (68.3%). The most common triad was the association of increased waist circumference, hypertension, and diabetes (in 25,5% of T2D and 20% of T1D). By comparing the population of diabetics with metabolic syndrome (MS) and those without, we noticed a significant difference (p<0.05) concerning age, gender, all components of MS (high blood pressure, abdominal obesity, hyper triglyceridemia (TG), and hypo high-density lipoprotein cholesterol (HDL-C). Diabetic retinopathy and ischemic heart disease were the only chronic complications correlated with MS (p <0.05). Conclusion High prevalence of metabolic syndrome in diabetic patients. Its screening and the specific treatment of its various components are essential in order to reduce the complications which jeopardize the functional as well as the vital prognosis of these patients.
目的 我们的研究旨在评估糖尿病患者中代谢综合征（MS）的患病率，确定其决定因素，并确定MS与退行性并发症之间的相关性。方法 在非斯哈桑二世大学医院内分泌、糖尿病和营养科进行了一项回顾性、描述性和分析性研究，研究时间为2009年1月至2019年1月。我们的研究纳入了所有1型和2型糖尿病患者。代谢综合征的存在根据国际糖尿病联盟（IDF）和美国心脏协会/美国国立心肺血液研究所（AHA/NHLBI）联合科学声明（2009年）的标准定义。数据录入Microsoft Excel（微软公司，2018年），并使用SPSS软件（IBM公司，2015年发布。IBM SPSS Statistics for Windows，版本23.0。纽约州阿蒙克：IBM公司）进行分析。结果 本研究共纳入1034例患者；78.7%为2型糖尿病（T2D）患者，21.3%为1型糖尿病（T1D）患者。T2D患者的平均年龄为52.06±17.33岁，T1D患者为27.04±9.66岁。65.5%为女性。T2D患者中代谢综合征的患病率为78.4%，T1D患者为27.3%。T2D患者中最常见的异常是高血压（87.7%），T1D患者中是内脏肥胖（68.3%）。最常见的三联征是腰围增加、高血压和糖尿病的组合（T2D患者中占25.5%，T1D患者中占20%）。通过比较患有代谢综合征（MS）的糖尿病患者群体和未患代谢综合征的患者群体，我们注意到在年龄、性别、MS的所有组成部分（高血压、腹部肥胖、高甘油三酯血症（TG）和低高密度脂蛋白胆固醇（HDL-C））方面存在显著差异（p<0.05）。糖尿病视网膜病变和缺血性心脏病是仅与MS相关的慢性并发症（p<0.05）。结论 糖尿病患者中代谢综合征的患病率较高。对其进行筛查并对其各个组成部分进行针对性治疗对于减少危及这些患者功能和生命预后的并发症至关重要。
